MVMarta Valero

Marta Valero

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Marta Valero has a total of 61 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Multicenter Study of Secukinumab Uptitration in Axial Spondyloarthritis: Real-World Evidence

    by Dalifer Freites Núñez, Adela Gallego, Alicia García Dorta, Andrea García-Valle, Marta Valero Expósito, Isabel De la Morena Barrio, Celia Arconada, Cristina Valero, Manuel Fernández-Prada, Marta López I Gómez, et al.

    Objective: To evaluate the real-world effectiveness, treatment retention, and safety of secukinumab (SEC) uptitration to 300 mg in patients with axial spondyloarthritis (axSpA), including radiographic (r-axSpA) and nonradiographic (nr-axSpA) subtypes, with active disease despite receiving SEC 150 mg every 4 weeks. Methods: This multicenter, retrospective study included patients with axSpA who had received SEC 150 mg for ≥ 3 months and had active disease (Axial Spondyloarthritis Disease Activity Score [ASDAS] ≥ 2.1) at the time of dose escalation. Patients were followed for up to 24 months after escalation. Effectiveness was assessed through changes in ASDAS over time. Treatment retention was analyzed using Kaplan-Meier curves, with factors associated with discontinuation explored by Cox regression. Safety outcomes were reported as incidence of adverse events (AEs). Results: Among 106 patients (77 r-axSpA, 29 nr-axSpA), ASDAS significantly declined within 6 months and was sustained through 24 months. Median ASDAS decreased from 4.1 to 2.0 in patients with r-axSpA and from 4.1 to 2.0 in those with nr-axSpA. Overall, 85.9% of patients achieved ASDAS ≤ 2.1 at least once after escalation. Retention of SEC 300 mg was 87.8% at 6 months and 59.1% at 24 months, with no significant difference between subtypes (log-rank P = 0.48). HLA-B27 positivity showed a nonsignificant trend toward higher discontinuation risk. AE incidence was 15.79 per 100 patient-years, and AEs were mostly mild infections and cutaneous reactions. No new safety signals were identified. Conclusion: SEC uptitration to 300 mg was associated with sustained improvements in disease activity and favorable retention and safety in axSpA patients with active disease after receiving SEC 150 mg, supporting dose escalation as a clinically effective and safe strategy.


  • Open Access

    Seventeen-year reassessment of diagnostic transitions, biologic therapy initiation and mortality in spondyloarthritis: results from the REGISPON-3 study

    by María Ángeles Puche-Larrubia, Lourdes Ladehesa-Pineda, María Carmen Ábalos-Aguilera, Desirée Ruiz-Vílchez, Laura Berbel-Arcobé, Xavier Juanola-Roura, Marta Arévalo-Salaet, Mireia Moreno, Raquel Almodóvar-González, Cristina Pijoan-Moratalla, et al.

    Objectives: To evaluate disease evolution, diagnostic transitions, time to biologic treatment initiation and mortality in patients with spondyloarthritis (SpA) after 17 years from the original Spanish Registry of Spondyloarthritis (REGISPONSER). Methods: Spondyloarthritis Registry 3 (REGISPON-3) is a two-timepoint longitudinal study with patients fulfilling the European Spondyloarthropathy Study Group criteria participating in the REGISPONSER study and re-evaluated after 17 years. Clinical, laboratory, radiological and treatment data were collected and compared with baseline. Diagnostic changes according to the rheumatologist’s judgement and their associated factors were analysed using multivariable logistic regression. Time to initiation of biologic therapy was evaluated using Kaplan-Meier survival analysis. Results: A total of 536 patients from the REGISPONSER study conducted in 2004 were contacted in 2021 for the REGISPON-3 visit. Of these, 411 were physically re-evaluated, while 125 were confirmed deceased. Among the 411 patients, 31.6% experienced a change in diagnosis in the REGISPON-3 visit, mainly from undifferentiated SpA to axial SpA or psoriatic arthritis. In multivariable analysis, dactylitis, younger age and lower Bath Ankylosing Spondylitis Radiology Index scores were associated with diagnostic change. The use of biologic disease-modifying antirheumatic drugs (bDMARDs) increased from 13.1% to 52.1%. However, the median time to first bDMARD from symptom onset was 32 years (95% CI 30 to 35) and 28 years from diagnosis (95% CI 26 to 32). Among the 125 patients who died, the leading causes were infections (21.6%), cardiovascular (CV) events (20.0%) and cancer (19.2%). Conclusions: This long-term reassessment reveals significant diagnostic changes in SpA and a mortality burden mainly attributed to infections and CV diseases.


  • Osteomalacia: A Challenging Diagnosis Adverse Event Associated with Intravenous Ferric Carboxymaltose—A Case Report

    by Mauro Ferre-Sanfrancisco, Iván del Bosque Granero, Marta Valero Expósito, Mónica Vázquez Díaz

    Hypophosphatemia resulting from intravenous iron treatment has become an increasingly concerning syndrome in recent years. We report the case of a 66-year-old male patient with a medical history of ankylosing spondylitis (AS), Crohn’s disease, and chronic iron deficiency. Following intravenous iron infusions of ferric carboxymaltose, the patient developed diffuse bone pain and multiple bone fractures. After ruling out that the pain was in the context of spondyloarthritis (SpA), the diagnosis of osteomalacia associated with hypophosphatemia was established based on his clinical history, complementary analytical, and imaging tests. Once the diagnosis was made, intravenous ferric carboxymaltose infusions were discontinued, and oral calcium and vitamin D supplementation were initiated, resulting in clinical improvement with serum phosphate levels’ normalization. This case shows the importance of recognizing the risk factors and clinical findings in selected patients, monitoring phosphate levels in those with high risk factors and considering stopping or switching to another intravenous iron formulation. Furthermore, this case highlights the importance of maintaining clinical suspicion of other possible etiologies of pain in patients with SpA.


  • Open Access

    Correction: Factors associated with discontinuation of biologics in patients with inflammatory arthritis in remission: data from the BIOBADASER registry

    by Marta Valero, Carlos Sanchez-Piedra, Mercedes Freire, Maria Colazo, Noemi Busquets, Erardo Merino-Ibarra, Carlos Rodriguez-Lozano, Sara Manrique, Cristina Campos, Fernando Sanchez-Alonso, et al.

  • Open Access

    Factors associated with discontinuation of biologics in patients with inflammatory arthritis in remission: data from the BIOBADASER registry

    by Marta Valero, Carlos Sánchez-Piedra, Mercedes Freire, María Colazo, Noemí Busquets, Erardo Meriño-Ibarra, Carlos Rodríguez-Lozano, Sara Manrique, Cristina Campos, Fernando Sánchez-Alonso, et al.

    Background: The objectives of this study were to assess the discontinuation of biologic therapy in patients who achieve remission and identify predictors of discontinuation of biologics in patients with inflammatory arthritis in remission. Methods: An observational retrospective study from the BIOBADASER registry comprising adult patients diagnosed with rheumatoid arthritis (RA), ankylosing spondylitis (AS), or psoriatic arthritis (PsA) and receiving 1 or 2 biological disease-modifying drugs (bDMARDs) between October 1999 and April 2021. Patients were followed yearly after initiation of therapy or until discontinuation of treatment. Reasons for discontinuation were collected. Patients who discontinued bDMARDs because of remission as defined by the attending clinician were studied. Predictors of discontinuation were explored using multivariable regression models. Results: The study population comprised 3,366 patients taking 1 or 2 bDMARDs. Biologics were discontinued owing to remission by 80 patients (2.4%): 30 with RA (1.7%), 18 with AS (2.4%), and 32 with PsA (3.9%). The factors associated with a higher probability of discontinuation on remission were shorter disease duration (OR: 0.95; 95% CI: 0.91–0.99), no concomitant use of classic DMARDs (OR: 0.56; 95% CI: 0.34–0.92), and longer usage of the previous bDMARD (before the decision to discontinue biological therapy) (OR: 1.01; 95% CI: 1.01–1.02); in contrast, smoking status (OR: 2.48; 95% CI: 1.21–5.08) was associated with a lower probability. In patients with RA, positive ACPA was associated with a lower probability of discontinuation (OR: 0.11; 95% CI: 0.02–0.53). Conclusions: Discontinuation of bDMARDs in patients who achieve remission is uncommon in routine clinical care. Smoking and positive ACPA in RA patients were associated with a lower probability of treatment discontinuation because of clinical remission.


  • Open Access

    Retention rate of secukinumab in psoriatic arthritis: Real-world data results from a Spanish multicenter cohort

    by Marta Valero-Expósito, María Martín-López, Carlos Guillén-Astete, Beatriz Joven, Carolina Merino-Argumanez, Valentina Emperiale, Jose Campos, Ana Pérez, Javier Bachiller-Corral

    Secukinumab is a novel anti-IL17 biologic treatment approved for the treatment of psoriatic arthritis (PsA). The purpose of the present study is to identify factors that can condition the retention rate of this drug in a real-world scenario. Methods: A multicentric retrospective study was conducted based on the registries of consecutive patients diagnosed with PsA who started secukinumab from January 2016 to December 2018. For purposes of Cox-regression analysis, the time spanning from the first administration of secukinumab until its interruption or the end of the follow-up was considered the independent variable. Variables of known relevance and those who demonstrated direct association with the drug retention rate were included in the model. Results: One hundred seventy-six registries were analyzed (average age at diagnosis 44.7 ± 12.1 years old, 114 females). The median retention rate of secukinumab was 636 days (95% confidence interval [CI] 542.4–729.5). Presence of peripheral arthritis (hazard ratio 0.424 [95% CI 0.213–0.847, P = .015]) and a time of evolution >6 years (hazard ratio 0.468 [95% CI 0.225–0.975, P = .043]) were the 2 variables that showed a significant influence on the drug retention rate. According to our results, patients who exhibit peripheral arthritis and those with a higher evolution time will have more probabilities of a larger secukinumab retention rate.


  • 4337 Dosimetrie patient en radiologie classique

    by H. Beauvais-March, J.F. Chateil, M. Valéro

  • 1337 Dosimetrie patient en radiologie classique

    by H. Beauvais-March, J.F. Chateil, M. Valéro